Lonza to buy US biologics site from Roche for US$ 1.2 billion

Lonza plans to invest approximately CHF 500 million to upgrade the facility

Eris Lifesciences buys India formulation business of Biocon Biologics for Rs. 1,242 Cr

Both organisations enter into a long- term collaboration to expand patient access in India

Syngene biologics facility to be operational for US, European customers from mid-year

New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day

Evonik Vland Biotech JV commences operations

Grand opening of the joint venture between Evonik China and Shandong Vland Biotech in Qingdao, China

Indranil Sen, CFO, Biocon resigned

Sen spent a decade with Biocon and held various key roles,

CuraTeQ Biologics announces the successful Phase 1 clinical study outcome of their BP11 product

AbCellera and Biogen collaborate on neurological antibody therapy

AbCellera will receive an upfront payment and is eligible to receive additional milestone payments

Biomanufacturing and Bio-foundry will drive India’s future bioeconomy: Dr. Jitendra Singh

India has reached to nearly 6,000 bio-startups from 50 in the past 10 years

Biocon Biologics secures Canada market entry date for YESAFILI

This agreement paves the way for the introduction of YESAFILI into the Canadian market

Biocon appoints Vishal Nayyar as Head – SCM and Amit Kaptain as Head Commercials - API